DE60038567D1 - Modifiziertes gp100 und dessen verwendung - Google Patents
Modifiziertes gp100 und dessen verwendungInfo
- Publication number
- DE60038567D1 DE60038567D1 DE60038567T DE60038567T DE60038567D1 DE 60038567 D1 DE60038567 D1 DE 60038567D1 DE 60038567 T DE60038567 T DE 60038567T DE 60038567 T DE60038567 T DE 60038567T DE 60038567 D1 DE60038567 D1 DE 60038567D1
- Authority
- DE
- Germany
- Prior art keywords
- nucleic acid
- tumor antigen
- modified
- vaccines
- inducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000001926 lymphatic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6494—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24071—Demonstrated in vivo effect
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16087999P | 1999-10-22 | 1999-10-22 | |
US160879P | 1999-10-22 | ||
US22332500P | 2000-08-07 | 2000-08-07 | |
US223325P | 2000-08-07 | ||
PCT/CA2000/001254 WO2001030847A1 (en) | 1999-10-22 | 2000-10-20 | Modified gp100 and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60038567D1 true DE60038567D1 (de) | 2008-05-21 |
DE60038567T2 DE60038567T2 (de) | 2009-05-14 |
Family
ID=26857297
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60038971T Expired - Lifetime DE60038971D1 (de) | 1999-10-22 | 2000-10-20 | Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene |
DE60038567T Expired - Lifetime DE60038567T2 (de) | 1999-10-22 | 2000-10-20 | Modifiziertes gp100 und dessen verwendung |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60038971T Expired - Lifetime DE60038971D1 (de) | 1999-10-22 | 2000-10-20 | Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene |
Country Status (10)
Country | Link |
---|---|
US (4) | US8017590B1 (de) |
EP (4) | EP1808180A3 (de) |
JP (2) | JP4540033B2 (de) |
AT (2) | ATE395930T1 (de) |
AU (2) | AU1013701A (de) |
CA (3) | CA2721011A1 (de) |
DE (2) | DE60038971D1 (de) |
DK (1) | DK1227837T3 (de) |
ES (1) | ES2306670T3 (de) |
WO (2) | WO2001030382A1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2721011A1 (en) * | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
CA2408328C (en) | 2000-05-10 | 2012-04-17 | Aventis Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
CA2416893A1 (en) * | 2000-07-31 | 2002-02-07 | Aventis Pasteur Limited | Modified cea and uses thereof |
US8236776B2 (en) * | 2002-04-09 | 2012-08-07 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
AU2003223527B2 (en) | 2002-04-09 | 2009-01-15 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
AU2004211481A1 (en) * | 2003-02-13 | 2004-08-26 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof |
US8207314B2 (en) * | 2003-05-16 | 2012-06-26 | Sanofi Pasteur Limited | Tumor antigens for prevention and/or treatment of cancer |
DE602004028468D1 (de) * | 2003-06-17 | 2010-09-16 | Mannkind Corp | Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke |
AU2011213698B2 (en) * | 2003-06-17 | 2013-10-31 | Mannkind Corporation | Method to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
BRPI0413334A (pt) * | 2003-09-05 | 2006-10-10 | Sanofi Pasteur Ltd | vetores de multiantìgenos para melanoma |
KR101162970B1 (ko) | 2003-10-08 | 2012-07-12 | 테리온 바이오로직스, 인크. | 변형된 cea/b7 벡터 |
EP1716173B8 (de) * | 2004-02-11 | 2012-06-27 | Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. | Fusionsproteine des karzinomembryonalen antigens und deren verwendungen |
WO2006071989A2 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
DE102005041616B4 (de) * | 2005-09-01 | 2011-03-17 | Johannes-Gutenberg-Universität Mainz | Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen |
WO2009006479A2 (en) | 2007-07-02 | 2009-01-08 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
EP2326340A4 (de) * | 2008-09-11 | 2013-01-23 | Univ Ben Gurion | Zusammensetzungen und verfahren zur behandlung von pneumokokkeninfektionen |
WO2011050344A2 (en) * | 2009-10-23 | 2011-04-28 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
NZ616304A (en) | 2011-04-08 | 2016-01-29 | Immune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
EP3242940B1 (de) | 2015-01-09 | 2023-03-29 | Etubics Corporation | Verfahren und zusammensetzungen für kombinationsimmuntherapie |
US10695417B2 (en) | 2015-01-09 | 2020-06-30 | Etubics Corporation | Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein |
EP3286213B1 (de) | 2015-04-20 | 2021-08-04 | Etubics Corporation | Verfahren und zusammensetzungen für eine kombinationsimmuntherapie |
US10610590B2 (en) | 2016-05-02 | 2020-04-07 | Symbios Technologies, Inc. | Electrochemical plasma activated aqueous chemotherapeutics |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
SG11202109591QA (en) * | 2019-03-04 | 2021-10-28 | Univ Health Network | T cell receptors and methods of use thereof |
Family Cites Families (173)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US4168062A (en) | 1977-12-05 | 1979-09-18 | Mccarthy Gerald F | Automated goalie |
US4258029A (en) | 1979-04-23 | 1981-03-24 | Connaught Laboratories Limited | Synthetic adjuvants for stimulation of antigenic responses |
US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US5378457A (en) | 1981-12-24 | 1995-01-03 | Virogenetics Corporation | Interferon sensitive recombinant poxvirus vaccine |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4882278A (en) | 1983-04-29 | 1989-11-21 | President And Fellows Of Harvard College | Non-toxinogenic vibrio cholerae mutants |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
NZ214716A (en) | 1985-01-07 | 1989-04-26 | Syntex Inc | 1,2-dialkoxy-omega-trialkylammonium cationic surfactants |
DE3521994A1 (de) | 1985-06-20 | 1987-01-02 | Bayer Ag | N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
US5141742A (en) | 1986-02-07 | 1992-08-25 | Oncogen | Vaccines against melanoma |
US5122599A (en) | 1986-08-13 | 1992-06-16 | Molecular Diagnostics, Inc. | CDNAS coding for members of the carcinoembryonic antigen family |
US5015580A (en) | 1987-07-29 | 1991-05-14 | Agracetus | Particle-mediated transformation of soybean plants and lines |
US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
EP0347425B1 (de) | 1987-03-02 | 1995-12-27 | Whitehead Institute For Biomedical Research | Rekombinant-mykobakterielle impfstoffe |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US6699475B1 (en) | 1987-09-02 | 2004-03-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
JPH01193227A (ja) | 1988-01-29 | 1989-08-03 | Res Dev Corp Of Japan | 癌免疫療法補助剤 |
EP0326423B1 (de) | 1988-01-29 | 1995-05-24 | Eli Lilly And Company | Vektoren, Zusammensetzungen und Verfahren zur Expression von einem menschlichen Adevoharzimomantigen |
US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
US5093258A (en) | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
US6780407B1 (en) | 1989-03-08 | 2004-08-24 | Aventis Pasteur | Pox virus comprising DNA sequences encoding CEA and B7 antigen |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
ES2200016T3 (es) | 1989-03-21 | 2004-03-01 | Vical Incorporated | Expresion de secuencias polinucleotidicas exogenas en un vertebrado. |
US5076908A (en) | 1989-07-19 | 1991-12-31 | Chevron Research & Technology Company | Method and apparatus for an on-stream particle replacement system for countercurrent contact of a gas and liquid feed stream with a packed bed |
JPH05504067A (ja) | 1990-02-26 | 1993-07-01 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション | 大腸菌及びマイコバクテリアのためのシャトルプラスミド |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
GB9015888D0 (en) | 1990-07-19 | 1990-09-05 | Smithkline Biolog | Vectors |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
WO1992011354A1 (en) | 1990-12-18 | 1992-07-09 | The General Hospital Corporation | VIBRIO CHOLERAE STRAINS DEFECTIVE IN irgA EXPRESSION, AND CHOLERA VACCINES DERIVED THEREFROM |
CA2097931C (en) | 1990-12-18 | 2003-07-29 | Samuel I. Miller, Iii | Salmonella vaccines |
US5843456A (en) * | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
EP0575491B1 (de) | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Gentechnologisch hergestellter stamm für impfstoffe |
CA2102623C (en) | 1991-05-06 | 2003-04-22 | Jeffrey Schlom | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
AU2185592A (en) | 1991-06-06 | 1993-01-08 | Med Immune, Inc. | Induction of ctl responses to foreign antigens expressed in mycobacteria |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
US5637483A (en) | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
US5904920A (en) | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
JP3881689B2 (ja) | 1992-03-11 | 2007-02-14 | パウダージェクト ヴァクシンズ,インコーポレイテッド | 免疫不全ウイルス用の遺伝子ワクチン |
JPH07505283A (ja) | 1992-03-20 | 1995-06-15 | ベイラー・カレッジ・オブ・メディシン | Dnaトランスポーター系および使用方法 |
EP1236473A3 (de) | 1992-04-03 | 2003-01-15 | The Regents Of The University Of California | Selbst zusammenbaubares system zur verabreichung von polynukleotiden |
HU219808B (hu) | 1992-06-25 | 2001-08-28 | Smithkline Beecham Biologicals S.A. | Adjuvánst tartalmazó vakcinakompozíció és eljárás annak előállítására |
ATE242319T1 (de) | 1992-07-06 | 2003-06-15 | Harvard College | Deletionsmutanten als impfstoffe gegen cholera |
EP0651656A1 (de) | 1992-07-08 | 1995-05-10 | Schering Corporation | Verwendung von gm-csf als impfstoffadjuvanz |
US6222012B1 (en) | 1992-08-31 | 2001-04-24 | Ludwig Institute For Cancer Research | Isolated nonapeptides presented by HLA molecules, and uses thereof |
US5462871A (en) | 1992-08-31 | 1995-10-31 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode MAGE derived nonapeptides |
US5405940A (en) | 1992-08-31 | 1995-04-11 | Ludwig Institute For Cancer Research | Isolated nonapeptides derived from MAGE genes and uses thereof |
US5744316A (en) | 1992-12-22 | 1998-04-28 | Ludwig Institute For Cancer Research | Isolated, tyrosinase derived peptides and uses thereof |
US5519117A (en) | 1992-12-22 | 1996-05-21 | Ludwig Institute For Cancer Research | Isolated, tyrosinase derived peptides and uses thereof |
DK0681483T3 (da) | 1993-01-26 | 2005-11-21 | Univ Pennsylvania | Præparater og fremgangsmåder til administration af genetisk materiale |
CA2156191A1 (en) | 1993-02-22 | 1994-09-01 | Stephen B. Calderwood | Heterologous antigens in live cell vaccine strains |
US5869445A (en) | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
IL108915A0 (en) | 1993-03-18 | 1994-06-24 | Merck & Co Inc | Polynucleotide vaccine against influenza virus |
DE69405551T3 (de) | 1993-03-23 | 2005-10-20 | Smithkline Beecham Biologicals S.A. | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
TW360548B (en) | 1993-04-08 | 1999-06-11 | Powderject Res Ltd | Products for therapeutic use |
SG54115A1 (en) | 1993-04-27 | 1998-11-16 | Gerber Scient Products Inc | Thermal printing apparatus with improved power supply |
US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
US5562909A (en) | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
EP0708637B1 (de) | 1993-07-14 | 2004-01-28 | The Regents of the University of California | Sich selbst zusammensetzendes polynukleotid-abgabesystem, das dendrimer-polykationen enthält |
NZ271774A (en) | 1993-08-06 | 1998-02-26 | Cytel Corp | Immunogenic peptides from the c-terminus of the mage-1 (melanoma) antigen |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
TW442569B (en) | 1993-10-25 | 2001-06-23 | Canji Inc | Recombinant adenoviral vector |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5554724A (en) | 1994-03-24 | 1996-09-10 | University Of Leiden | Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof |
US5554506A (en) | 1994-03-24 | 1996-09-10 | Ludwig Institute For Cancer Research | Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof |
US5651981A (en) | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
SE9401091D0 (sv) | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
US5874560A (en) | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
EP0756604A1 (de) * | 1994-04-22 | 1997-02-05 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Melanoma antigene |
US5759535A (en) | 1994-05-13 | 1998-06-02 | Research Corporation Technologies, Inc. | Immunotherapeutic strategies for the treatment of cancer |
SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
US6060257A (en) | 1994-06-03 | 2000-05-09 | Ludwig Institute For Cancer Research | Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof |
US20030072774A1 (en) | 1994-06-10 | 2003-04-17 | Diane M. Gajewczyk | Proteinaceous adjuvants |
CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6019982A (en) | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
US5527928A (en) | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
US6045802A (en) | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
CA2201592A1 (en) | 1994-10-03 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
EP1016418B1 (de) | 1994-10-03 | 2009-12-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
FR2726764B1 (fr) | 1994-11-14 | 1997-01-31 | Pasteur Merieux Serums Vacc | Adjuvant pour composition vaccinale |
US5843648A (en) | 1995-01-10 | 1998-12-01 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods |
US6001349A (en) | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
EP0843731B1 (de) | 1995-03-24 | 2008-02-13 | Genzyme Corporation | Adenovirale vektoren für die gentherapie |
GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US5807978A (en) | 1995-06-07 | 1998-09-15 | Kokolus; William J. | Immunogenic peptides of prostate specific antigen |
US6127116A (en) * | 1995-08-29 | 2000-10-03 | Washington University | Functional DNA clone for hepatitis C virus (HCV) and uses thereof |
US6951917B1 (en) | 1995-09-26 | 2005-10-04 | The United States Of America As Represented By The Department Of Health And Human Services | MHC-class II restricted melanoma antigens and their use in therapeutic methods |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
WO1997015597A1 (en) | 1995-10-25 | 1997-05-01 | Centocor B.V. | HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE |
WO1997020575A1 (en) | 1995-12-08 | 1997-06-12 | The University Of Alabama At Birmingham Research Foundation | Targeted adenovirus vectors |
EP0879284B1 (de) * | 1996-01-30 | 2009-07-29 | The Regents of The University of California | Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung. |
US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
US6083703A (en) | 1996-02-09 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes |
US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
FR2746110B1 (fr) | 1996-03-14 | 1998-04-17 | Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants | |
EP0921805A4 (de) | 1996-03-19 | 2002-06-26 | Univ Virginia | Peptide, die von melanomspezifischen a1-, a2- und a3-beschränkten zytotoxischen lymphozyten erkannt werden, sowie deren verwendungen |
WO1997039771A1 (en) | 1996-04-22 | 1997-10-30 | The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Heterologous boosting immunizations |
FR2748753B1 (fr) | 1996-05-20 | 1998-08-14 | Transgene Sa | Nouveaux vecteurs adenoviraux pour la therapie genique |
WO1997047271A2 (en) * | 1996-06-12 | 1997-12-18 | Yajun Guo | Cellular vaccines and immunotherapeutics and methods for their preparation |
US20050136066A1 (en) | 1996-06-12 | 2005-06-23 | Yajun Guo | Cellular vaccines and immunotherapeutics and methods for their preparation |
US6805869B2 (en) | 1996-06-12 | 2004-10-19 | Shanghai Cp Guojian Pharmaceutical Co., Ltd. | Cellular vaccines and immunotherapeutics and methods for their preparation |
US20040156861A1 (en) | 1996-07-11 | 2004-08-12 | Figdor Carl Gustav | Melanoma associated peptide analogues and vaccines against melanoma |
SE510778C2 (sv) | 1996-07-11 | 1999-06-21 | Sandvik Ab | Belagt skär för finfräsning av grått gjutjärn |
ZA975858B (en) * | 1996-07-11 | 1998-09-01 | Akzo Nobel Nv | Melanoma associated peptide analogues and vaccines against melanoma |
CA2261990A1 (en) * | 1996-07-25 | 1998-02-05 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
US6265215B1 (en) | 1996-09-13 | 2001-07-24 | Ludwig Institute For Cancer Research | Isolated peptides which complex with HLA-Cw16 and uses thereof |
AU729690B2 (en) | 1996-10-10 | 2001-02-08 | Henrik Garoff | Alphavirus-retrovirus vectors |
ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
GB9621680D0 (en) | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
WO1998017815A1 (en) | 1996-10-17 | 1998-04-30 | Oxford Biomedica (Uk) Limited | Retroviral vectors |
KR100620481B1 (ko) * | 1996-10-23 | 2006-09-06 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개선된 백신 |
US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
US7255862B1 (en) * | 1996-11-14 | 2007-08-14 | Connaught Technology Corporation | ALVAC/FIV constructs |
AU735459B2 (en) | 1997-01-30 | 2001-07-12 | University Of Virginia Patent Foundation | Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor |
JP2001513643A (ja) | 1997-03-06 | 2001-09-04 | ウーベルラ、クラウス | レンチウイルスをベースとするベクター及びベクター系 |
US5990091A (en) | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
AU7158398A (en) | 1997-04-17 | 1998-11-11 | Regents Of The University Of California, The | Use of lentiviral vectors for antigen presentation in dendritic cells |
WO1998051810A1 (en) | 1997-05-13 | 1998-11-19 | University Of North Carolina At Chapel Hill | Lentivirus-based gene transfer vectors |
GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
CN1313481C (zh) | 1997-06-23 | 2007-05-02 | 路德维格癌症研究所 | 结合hla分子的分离的九肽和十肽及其应用 |
WO1998058956A2 (en) | 1997-06-23 | 1998-12-30 | Ludwig Institute For Cancer Research | Methods for inducing an immune response involving prime-boost protocols |
AU707186B2 (en) * | 1997-07-01 | 1999-07-01 | Transgene S.A. | Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy |
US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
EP2286831A1 (de) * | 1997-07-10 | 2011-02-23 | Mannkind Corporation | Methode zur Induktion von zytotoxischen T-cell Antworten |
US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
AU734180B2 (en) | 1997-08-29 | 2001-06-07 | Antigenics Llc | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
AU4110097A (en) | 1997-08-29 | 1999-03-22 | Sue-May Kang | Method and apparatus for voluntary motor controlled convalescence |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
WO2000000600A2 (en) | 1997-09-22 | 2000-01-06 | Chang Lung Ji | Lentiviral vectors, comprising modified major donor splice sites and major packaging signals |
ES2245042T3 (es) | 1997-09-24 | 2005-12-16 | The Regents Of The University Of California | Vectores de lentivirus de no primates y sistemas de empaquetamiento. |
WO1999018206A2 (en) | 1997-10-08 | 1999-04-15 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Human cancer antigen ny eso-1/cag-3 and gene encoding same |
US6756038B1 (en) | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
ATE364048T1 (de) | 1997-10-10 | 2007-06-15 | Us Gov Health & Human Serv | Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität |
US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
AU1087299A (en) | 1997-10-14 | 1999-05-03 | Avant Immunotherapeutics, Inc. | Non-integrating dna vector of retroviral origin having high-protein expres sion, and secreted immunogenic antigens |
AU1539499A (en) | 1997-11-25 | 1999-06-15 | Princeton University | Method for preparing adenovirus vectors, vectors so prepared, and uses thereof |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
KR20010033062A (ko) | 1997-12-12 | 2001-04-25 | 루이기 낼다이니 | 렌티바이러스성 벡터의 치료학적 용도 |
GB9726555D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
US6709844B1 (en) | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
WO1999046988A1 (en) * | 1998-03-20 | 1999-09-23 | Genzyme Corporation | Compositions and methods for antigen-specific vaccination |
JP2002506618A (ja) * | 1998-03-20 | 2002-03-05 | ジェンザイム・コーポレーション | 腫瘍自己抗原に対する免疫誘導 |
EP1064305B1 (de) | 1998-03-27 | 2004-09-15 | The Secretary of State for Defence | Rekombinantes virus |
US6171855B1 (en) | 1998-05-28 | 2001-01-09 | The Regents Of The University Of Michigan | Vectors |
CA2330211A1 (en) | 1998-06-08 | 1999-12-16 | Karel Petrak | Formulations for electroporation |
US20030022854A1 (en) * | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
EP1117679B9 (de) | 1998-10-02 | 2010-07-07 | Ludwig Institute For Cancer Research | Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden |
US6407063B1 (en) | 1998-10-02 | 2002-06-18 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
CA2678259C (en) * | 1998-12-09 | 2016-10-18 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
EP1619254B1 (de) | 1999-09-09 | 2010-12-22 | CureVac GmbH | Transfer von mRNA unter Verwendung von polykationischen Verbindungen |
CA2721011A1 (en) * | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
EP2314712B1 (de) | 2001-11-07 | 2014-01-08 | Mannkind Corporation | Für Epitope von Antigenen kodierende Expressionsvektoren sowie Verfahren zu deren Konzeption |
NL1023791C2 (nl) | 2003-07-01 | 2005-01-04 | Lely Entpr Ag | Melkinstallatie. |
-
2000
- 2000-10-20 CA CA2721011A patent/CA2721011A1/en not_active Abandoned
- 2000-10-20 WO PCT/CA2000/001253 patent/WO2001030382A1/en active IP Right Grant
- 2000-10-20 CA CA2388301A patent/CA2388301C/en not_active Expired - Fee Related
- 2000-10-20 AU AU10137/01A patent/AU1013701A/en not_active Abandoned
- 2000-10-20 AU AU10136/01A patent/AU1013601A/en not_active Abandoned
- 2000-10-20 EP EP07000096A patent/EP1808180A3/de not_active Withdrawn
- 2000-10-20 ES ES00971184T patent/ES2306670T3/es not_active Expired - Lifetime
- 2000-10-20 US US09/693,754 patent/US8017590B1/en not_active Expired - Fee Related
- 2000-10-20 JP JP2001532799A patent/JP4540033B2/ja not_active Expired - Fee Related
- 2000-10-20 CA CA2388337A patent/CA2388337C/en not_active Expired - Fee Related
- 2000-10-20 EP EP00971184A patent/EP1227837B1/de not_active Revoked
- 2000-10-20 DE DE60038971T patent/DE60038971D1/de not_active Expired - Lifetime
- 2000-10-20 DE DE60038567T patent/DE60038567T2/de not_active Expired - Lifetime
- 2000-10-20 WO PCT/CA2000/001254 patent/WO2001030847A1/en active IP Right Grant
- 2000-10-20 EP EP08009203.4A patent/EP1964573B1/de not_active Expired - Lifetime
- 2000-10-20 AT AT00971184T patent/ATE395930T1/de active
- 2000-10-20 AT AT00971185T patent/ATE391726T1/de active
- 2000-10-20 EP EP00971185A patent/EP1228095B1/de not_active Expired - Lifetime
- 2000-10-20 DK DK00971184T patent/DK1227837T3/da active
- 2000-10-20 JP JP2001533844A patent/JP2003512829A/ja active Pending
-
2009
- 2009-10-22 US US12/604,320 patent/US20100260807A1/en not_active Abandoned
-
2011
- 2011-08-02 US US13/196,704 patent/US20110319480A1/en not_active Abandoned
-
2015
- 2015-03-04 US US14/637,415 patent/US20150352198A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE395930T1 (de) | 2008-06-15 |
EP1227837B1 (de) | 2008-05-21 |
EP1808180A3 (de) | 2010-12-22 |
CA2721011A1 (en) | 2001-05-03 |
EP1228095B1 (de) | 2008-04-09 |
EP1228095A1 (de) | 2002-08-07 |
EP1227837A1 (de) | 2002-08-07 |
ES2306670T3 (es) | 2008-11-16 |
US20150352198A1 (en) | 2015-12-10 |
EP1964573A3 (de) | 2011-03-02 |
CA2388337C (en) | 2013-01-08 |
CA2388301C (en) | 2011-01-04 |
WO2001030382A1 (en) | 2001-05-03 |
WO2001030847A1 (en) | 2001-05-03 |
DK1227837T3 (da) | 2008-09-15 |
EP1964573B1 (de) | 2014-11-26 |
AU1013601A (en) | 2001-05-08 |
US20100260807A1 (en) | 2010-10-14 |
CA2388301A1 (en) | 2001-05-03 |
DE60038567T2 (de) | 2009-05-14 |
ATE391726T1 (de) | 2008-04-15 |
JP2003512829A (ja) | 2003-04-08 |
AU1013701A (en) | 2001-05-08 |
JP4540033B2 (ja) | 2010-09-08 |
EP1808180A2 (de) | 2007-07-18 |
JP2003512437A (ja) | 2003-04-02 |
DE60038971D1 (de) | 2008-07-03 |
US20110319480A1 (en) | 2011-12-29 |
US8017590B1 (en) | 2011-09-13 |
EP1964573A2 (de) | 2008-09-03 |
CA2388337A1 (en) | 2001-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE391726T1 (de) | Modifiziertes gp100 und dessen verwendung | |
NO20001768D0 (no) | Viruskapsomervaksine, fremgangsmåte til fremstilling samt anvendelse derav | |
DE69030172T2 (de) | Impfstoffe gegen Krebs und Infektionskrankheiten | |
ATE413459T1 (de) | Herstellung von einer immunantwort gegen prostat- spezifisches antigen (spa) | |
CY1110533T1 (el) | Μεθοδοι και σκευασματα για νοσους σχετιζομενες με την αμυλοειδωση | |
ATE303161T1 (de) | Humanisierung von anti-carcinoembryonalen antigen anti-idiotypischen antikörper und dessen verwendung als tumorvakzin und zur markierung | |
BRPI9912663B1 (pt) | vacina contra cáncer e polipeptìdeo. | |
DK0668350T3 (da) | Melanomassocieret antigen, epitoper deraf samt vacciner mod melanom | |
TR200001646T2 (tr) | Bir salgılanmış meme kanseri proteini olan mamaglobin. | |
NO20013701D0 (no) | HER-2/neu-fusjonsproteiner | |
ATE347599T1 (de) | Tuberkulose impfstoff | |
ATE520713T1 (de) | Identifizierung und veränderung von immundominanten polypeptidepitopen | |
WO2001049317A3 (en) | Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen | |
ID30223A (id) | Penggunaan antibodi untuk vaksinasi melawan kanker | |
DK0522078T3 (da) | GP75 som en tumorvaccine mod melanom | |
NL300336I1 (nl) | Vaccin tegen de bof dat een jeryl-lynn virusstam bevat | |
HK1082666A1 (en) | Ihnv g fusion protein for immune stimulation | |
GB0409559D0 (en) | Polypeptide | |
EP1392358A4 (de) | Immunogene tumorantigene: für diese kodierende nukleinsäuren und polypeptide und verfahren zu ihrer verwendung | |
ATE166880T1 (de) | Impfstoff gegen cholera | |
RU2002107022A (ru) | Штамм Feline herpesvirus-1, используемый для контроля иммуногенной активности вакцин, изготовления специфических лечебно-профилактических и диагностических биопрепаратов | |
EA199900726A1 (ru) | Синтетические hiv gag гены |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |